Results 201 to 210 of about 70,416 (256)

Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs. [PDF]

Front Oncol
Bejjani N, Kattan J.
europepmc   +1 more source

Clinical utilities of platelet-derived growth factor signaling in breast cancer. [PDF]

Pharmacol Res
Reardon JJ, Mossing AA, Packard RL, Shah S, Sizemore GM.   +4 more
europepmc   +1 more source

Targeting Dynamin-Related Protein 1 and Glucose Metabolism Reverses Acquired Resistance to Sorafenib in Liver Cancer. [PDF]

Oncol Res
Che J, Chen Z, Zhang F, Zhu S, Cao S, Li O, Li R, Zheng J, Liu Y.   +8 more
europepmc   +1 more source

FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy. [PDF]

Blood Neoplasia
Menssen AJ, Ashango AB, Alonzo TA, Gerbing RB, Pardo L, Hsu FC, Lott LL, Dai F, Cooper TM, Pollard JA, Tarlock K, Aplenc R, Meshinchi S, Brodersen LE, Wells DA, Loken MR, Hudson CA.   +16 more
europepmc   +1 more source

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study. [PDF]

J Clin Med
Atas Ipek S, Yaslikaya S, Kara IO, Koseci T, Bayram E, Asarkaya E, Asoglu H, Turker M, Aykut A, Jeral Evinc S, Alan O, Yilmaz ME, Ates O, Yasar HA, Kayaalp M, Asik E, Yildirim A, Bacak B, Baykara M, Yurdatap Koc D, Hacioglu MB, Alkan S, Ekinci F, Agaoglu AB, Yilmaz M, Hacibekiroglu I, Karaca M, Guclu Kantar T, Gokoz Dogu G, Karacelik T, Eryilmaz MK, Sakalar T, Biter S, Kıdı MM, Aydınalp Camadan Y, Buyuksimsek M.   +35 more
europepmc   +1 more source

Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma. [PDF]

Chin Med J (Engl)
Zhao C, Zhang Y, Wang G, Chen W, Zhuang L, Gu S, Zheng J, Han L, Yu Z, Liu C, Liu D, Xie L, Xu J.   +12 more
europepmc   +1 more source

Nanomaterial-based strategies to overcome sorafenib resistance in hepatocellular carcinoma: from mechanistic insights to translational applications. [PDF]

Front Oncol
Huang J, Huang S, Chen W, Wang S, Zuo Z, Wu X, Deng G.   +6 more
europepmc   +1 more source

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States. [PDF]

Front Public Health
He Y, Jiang Q, Pan X, Deng L, Hu X, Yang Z, Lang W.   +6 more
europepmc   +1 more source

Gastrointestinal bleeding in hepatocellular carcinoma under systemic therapy: Real-world incidence and clinical predictors. [PDF]

Clinics (Sao Paulo)
Da Fonseca LG, Ikeoka LT, Sampaio EK, da Silveira THM, Yamamoto VJ, de Melo MAZ, Hoff PM, Sabbaga J.   +7 more
europepmc   +1 more source

Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients. [PDF]

Ther Adv Med Oncol
Arendt N, Payo-Serafín T, Kolosenko A, Kopsida M, Sjöblom M, Heindryckx F.   +5 more
europepmc   +1 more source